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ADP-ribosylation is a posttranslational modiﬁcation that exists in monomeric and polymeric
forms. Whereas the writers (e.g. ARTD1/PARP1) and erasers (e.g. PARG, ARH3) of poly-
ADP-ribosylation (PARylation) are relatively well described, the enzymes involved in mono-
ADP-ribosylation (MARylation) have been less well investigated. While erasers for the
MARylation of glutamate/aspartate and arginine have been identiﬁed, the respective
enzymes with speciﬁcity for serine were missing. Here we report that, in vitro,
ARH3 speciﬁcally binds and demodiﬁes proteins and peptides that are MARylated. Molecular
modeling and site-directed mutagenesis of ARH3 revealed that numerous residues are critical
for both the mono- and the poly-ADP-ribosylhydrolase activity of ARH3. Notably, a mass
spectrometric approach showed that ARH3-deﬁcient mouse embryonic ﬁbroblasts are
characterized by a speciﬁc increase in serine-ADP-ribosylation in vivo under untreated
conditions as well as following hydrogen peroxide stress. Together, our results establish
ARH3 as a serine mono-ADP-ribosylhydrolase and as an important regulator of the basal and
stress-induced ADP-ribosylome.
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ADP-ribosylation is an evolutionarily conserved covalentposttranslational modiﬁcation mainly catalyzed by ADP-ribosyltransferases (ARTs)1,2. These enzymes use nicoti-
namide adenine dinucleotide (NAD+) to transfer ADP-ribose
(ADPr) moieties onto speciﬁc amino acid residues of target
proteins3, leading to mono-ADP-ribosylation (MARylation),
or to build linear and branched chains of poly-ADP-ribose
(PARylation)2. To date, at least 16 different enzymes are known
to catalyze MARylation in mammals. Besides the cholera toxin-
like ARTs (ARTCs) ARTC1, 2, and 54, also the majority of
diphtheria toxin-like ARTs (ARTDs) and Sirtuins 4 and 6 have
been shown to possess MARylation activity5,6. Only ARTD1/2
and Tankyrase1/2 (ARTD5/6) were described to form PAR
chains2.
In contrast to PARylation1,7, the speciﬁc roles of MARylation are
less well established. Nonetheless, an increasing number of studies
suggests MARylation to be implicated in various cellular processes,
including immunomodulation, endoplasmic reticulum (ER) stress,
cytoskeleton rearrangement, cell metabolism, and host–pathogen
interactions8. Studying the enzymes that catalyze (mono-ARTs) and
demodify MARylation (mono-ADP-ribosyl(-acceptor) hydrolases,
mono-ARHs) is most instructive for understanding the physiolo-
gical role of MARylation. While the ARTCs have been shown to
speciﬁcally MARylate arginine sites, the target amino acids mod-
iﬁed by speciﬁc ARTDs are less well known. However, the following
amino acid residues are known to be ADP-ribosylated by mam-
malian ARTDs: glutamate, aspartate, lysine, arginine, and serine (E,
D, K, R, and S), with serine having been recently identiﬁed as the
major nuclear ADPr acceptor site9,10.
ADP-ribosylation of proteins is reversible. In mammals, two
enzymes, poly-ADP-ribose glycohydrolase (PARG) and ARH3,
are known to degrade PAR chains11–13. Whereas several cyto-
solic, mitochondrial and nuclear isoforms of PARG have been
described14, ARH3 seems to exist in only one isoform, which,
however, was reported to be likewise present in the cytosol,
mitochondria, and nucleus15. PARG has both endo- and
exo-glycosidase activities16–19, whereas ARH3 seems to exert only
exoglycosidase activity13. Besides PAR, ARH3 hydrolyzes
O-acetyl-ADP-ribose (OAADPR)20,21, a product of the Sir2-
catalyzed NAD+-dependent histone deacetylation reaction22–25,
to produce ADP-ribose in a time- and Mg2+-dependent reaction
and thus ARH3 could participate in two signaling pathways21.
ARH3 seems to be ubiquitously expressed in mouse and
human tissues12. The 39-kDa ARH3 shares amino acid sequence
similarity with both ARH1 and ARH2. Critical vicinal acidic
amino acids in ARH3, identiﬁed by mutagenesis (i.e., D77 and
D78), are located in a region similar to that required for activity
in ARH112.
In vivo nuclear and cytoplasmic PARylation induced by
hydrogen peroxide (H2O2) was rather degraded by ARH3 than by
PARG, suggesting an important physiological function of ARH3
in the oxidative stress response15. ARH3-deﬁcient (KO) mouse
embryonic ﬁbroblasts (MEFs) were more susceptible to H2O2-
induced cytotoxicity than wild-type (WT) MEFs and ARH3
expression in ARH3 KO MEFs reduced their sensitivity toward
H2O215.
The ﬁrst enzyme described to hydrolyze MARylation was
ARH1, which releases ADPr from arginine residues26. In contrast,
ARH3 does not hydrolyze mono-ADP-ribose-arginine nor
-cysteine, -diphthamide, or -asparagine bonds12,13,21. Recently,
others and we identiﬁed the mammalian proteins MACROD1,
MACROD2, and TARG/OARD1/C6ORF130 as novel glutamate-
and aspartate-speciﬁc mono-ADP-ribosylhydrolases27–29. A
hydrolase capable of releasing ADPr from other ADP-ribose
acceptor sites (e.g., serine or lysine residues) has until very
recently not been published30.
We report here that, when comparing ARH3 and PARG
activity, in addition to its PAR hydrolase activity ARH3 catalyzes
demodiﬁcation of MARylated proteins, as shown by in vitro
demodiﬁcation of ARTD8. Molecular modeling revealed amino
acids in the catalytic cleft of ARH3 that proved important for
both binding and hydrolysis of MARylated and PARylated pep-
tides. Owing to our recent advancements in mass spectrometric
ADP-ribosylome analyses, we are able to demonstrate the in vitro
as well as in vivo relevance of ARH3’s serine-mono-ARH activity
by a speciﬁc increase in unique serine-ADPr sites in enriched
ADP-ribosylated peptides and MEFs from ARH3-deﬁcient ani-
mals as compared to WT controls, respectively. Finally, we pro-
vide a rich dataset of ARH3-targeted proteins and their
corresponding ADP-ribosylation sites.
Results
ARH3 has mono-ADP-ribosyl-acceptor hydrolase activity.
When comparing the efﬁciency of PARG and ARH3 in PAR
degradation, we observed that ARH3 removed radioactively
labeled ADPr from automodiﬁed ARTD1 to an extent compar-
able to PARG but demodiﬁed transmodiﬁed recombinant H3 and
H2B histone tails almost completely (Fig. 1a, left panel, Supple-
mentary Fig. 1a). The quantiﬁcation of the assay revealed that
ARH3 removes 80% of the incorporated ADPr from the H3 tail,
whereas PARG hydrolyzed only approximately 30% (Fig. 1a, right
panel). To biochemically characterize the enzymatic reaction
catalyzed by ARH3 and PARG, we performed concentration- and
time-dependent experiments. ARH3, but not PARG, efﬁciently
demodiﬁed ARTD1-transmodiﬁed H3 histone tails, suggesting
that ARH3 not only degrades ARTD1-mediated PARylation but
also might be a mono-ADP-ribosylhydrolase (Supplementary
Fig. 1b, c). Since ARTD1 is known to poly-ADP-ribosylate its
target proteins, we chose a radioactive in vitro MARylation/de-
MARylation assay using the automodiﬁcation ability of ARTD8
known to be a mono-ART31. Intriguingly, in the demodiﬁcation
step using either PARG or ARH3, the radioactive signal was
substantially reduced (i.e., 80%) only in the presence of ARH3,
but not by PARG, indicating that indeed ARH3 has in vitro
mono-ARH activity (Fig. 1b).
Various residues regulate ARH3’s activity. Having established
that ARH3 has mono-ARH activity, we set out to study which
amino acids of the catalytic cleft of ARH3 are involved in MAR-
binding and/or MAR hydrolase activity. To identify the crucial
amino acids, we performed an automatic overlap of the three-
dimensional structures of ARH3 and the structurally related
bacterial mono-glycohydrolase DraG (PDB code 2WOE) (Fig. 1c,
left panel). The structural similarity was striking with an average
deviation of only 1.4 Å for >200 pairs of corresponding Cα atoms
(located mainly in the α-helices and close to the binding site of
ADPr) despite the sequence identity of only 25%. Most impor-
tantly, upon structural overlap of the DraG/ADPr complex, the
pose of ADPr ﬁtted in the structure of ARH3 (PDB code 2FP0)
with the distal ribose close to the two Mg2+ ions and without any
steric conﬂict except for the slight re-orientation of Y149 during
energy minimization (Fig. 1c, right panel). Thus we used the
structural overlap to identify one potentially catalytically impor-
tant water molecule and seven conserved amino acid residues
with the following potential functions: holding water molecules in
place (E41, D77), holding Mg2+ ion in place (D314, T317, E41),
and binding of substrate (i.e., adenine and phosphate) (S148,
H182, Y149) (Fig. 1c, right panel, and Supplementary Fig. 1d). To
strengthen these ﬁndings, the binding of ARH3 to MARylated
peptides was further studied by mutational analysis and by
comparison with results of previously described ARH3
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Fig. 1 ARH3 has mono-ARH activity. a Left panel: Recombinant H3 histone tail was in vitro ADP-ribosylated using recombinant ARTD1 in the presence of
32P-labeled NAD+. Equal fractions were left untreated (Input) or were treated with PARG or ARH3. Above: radioactivity exposure, below: Coomassie Blue-
stained poly-acrylamide gel. Right panel: Quantiﬁcation of a expressed as demodiﬁcation activity (=reduction of the radioactive signal, normalized to
amount of protein). Data represent means± SEM for n= 3 independent experiments, ***P< 0.0001 as determined by ANOVA. b Left panel:
Automodiﬁcation of recombinant ARTD8 in the presence of 32P-labeled NAD+ results in MAR-labeled ARTD8 (Input) that was subsequently treated with
recombinant PARG or ARH3. Above: radioactivity exposure, below: Coomassie Blue-stained poly-acrylamide gel. Right panel: Quantiﬁcation of b expressed
as demodiﬁcation activity (=reduction of the radioactive signal, normalized to amount of protein). Data represent means± SEM for n= 3 independent
experiments, ***P< 0.0001 as determined by ANOVA. c Left panel: Structural overlap of human ARH3 (green) and the DraG/ADPr complex (cyan). Right
panel: Zoom in the active site of ARH3 with side chains of key residues which were mutated (labels). The binding mode of ADPr (carbon atoms in cyan)
was obtained by energy minimization starting from the pose obtained by the structural overlap. d Coomassie Blue-stained membrane of pull-downs of
GST-ARH3 (left) or His-PARG using the biotinylated peptides with (H2B-ADPr) and without (H2B) modiﬁcation. Af1521 served as positive control. e
ARTD1 automodiﬁed in the presence of 32P-labeled NAD+ was subjected to demodiﬁcation using WT and different ARH3 mutants. Red labels: mutants
deﬁcient in binding to H2B-ADPr, green labels: mutants retaining binding to H2B-ADPr. f ARTD8 automodiﬁed in the presence of 32P-labeled NAD+ was
subjected to demodiﬁcation using WT and different ARH3 mutants. Red labels: mutants deﬁcient in binding to H2B-ADPr, green labels: mutants retaining
binding to H2B-ADPr
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mutants12,21. To test the binding to a MARylated peptide, we
established a pull-down assay using biotinylated synthetic ADP-
ribosylated peptides with sequences derived from histone H2B
tails (Supplementary Fig. 1e)10,32. As the synthesis of H2B
modiﬁed at position 2 (Glu/E) could not be achieved, Glu was
replaced by a Gln/Q32. This modiﬁcation renders the peptide
resistant to acyl migration and thus the linkage is not cleavable by
ADPr hydrolases, which allows the analysis of binding abilities in
the absence of hydrolysis32. Moreover, the binding assays were
performed at 4 °C, a temperature at which ARH3 activity is
greatly reduced (Supplementary Fig. 1f), strongly suggesting that
ARH3’s hydrolytic activity is absent during the binding assays.
The unmodiﬁed and modiﬁed peptides were bound to strepta-
vidin beads and incubated with either glutathione-S-transferase
(GST)-tagged ARH3 or His-tagged PARG. After pull-down,
Coomassie staining of the blotted membrane revealed a single
55 kDa band representing GST-ARH3 only when ADPr-modiﬁed
peptides were used for the pull-down, similar to Af1521 known to
be a strong binder of ADP-ribose33. PARG apparently neither
bound the unmodiﬁed nor the modiﬁed peptide under the tested
conditions (Fig. 1d). The data thus strongly suggest that ARH3,
but not PARG, is able to stably bind to MARylated peptides. To
substantiate that the above identiﬁed residues indeed play a role
for either MAR-binding or hydrolase activity of ARH3, we gen-
erated different amino acid point mutants (e.g., E41A, E41Q,
D77N, G115D, S148A, Y149A, H182A, D314A, and T317A) plus
a double alanine replacement for D77 and D78. MAR-binding
assays using the above described pull-down approach with che-
mically modiﬁed H2B peptides revealed six residues to be crucial
for binding of ARH3 to MARylated peptides (or overall
ARH3 structure) (E41, D77, G115, S148, Y149, and H182)
(Supplementary Fig. 2a). However, the E41A, the D77/78A as well
as the D314A and T317A mutants retained their MAR-binding
capacity. With respect to ARH3’s enzymatic activity, demodiﬁ-
cation assays using ARTD1 automodiﬁed with radioactively
labeled NAD+ showed that all identiﬁed residues including the
ones that seem to be dispensable for binding (i.e., see mutants
E41A, D77/78A and D314A) are crucial for the PAR hydrolase
activity of ARH3 (Fig. 1e), in line with previously published data13.
Similar results were obtained when analyzing H3 tails modiﬁed by
ARTD1 (Supplementary Fig. 2b). However, since the data with
ARTD1-modiﬁed targets does not allow a conclusion about the
MAR hydrolase activity per se but only about the combined PAR/
MAR hydrolase activity of ARH3, the same ARH3 mutants were
tested with automodiﬁed ARTD8, which acts as mono-ART and
therefore solely catalyzes MARylation (Fig. 1f). These experiments
revealed that most of the tested ARH3 mutants also lost their
activity to demodify MARylated ARTD8. Only E41A retained weak
activity, although not to the same extent compared to WT ARH3.
In contrast, the E41Q mutant completely lost the mono-ADP-
ribosyl-hydrolase activity, which is most likely due to its loss of
ADP-ribose binding capacity.
In summary, while some of the tested ARH3 mutants were still
able to bind the MARylated peptide, the D77, D78, G115, S148,
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Y149, H182, D314, and T317 ARH3 mutants lost the ability to
demodify both PARylated and MARylated target proteins,
whereas the amino acid residue E41 proved to be slightly less
important for the demodiﬁcation of MARylated target proteins.
ARH3 hydrolyzes serine ADP-ribosylation in vitro. To address
which ADPr acceptor sites can be demodiﬁed by ARH3, we
applied a label-free quantiﬁcation (LFQ) mass spectrometry (MS)
approach, which was previously applied by our group34. We
used H2O2-stressed HeLa cells as a model system to generate
a broad array of ADP-ribosylated proteins35. To prevent ADP-
ribosylation and de-ADP-ribosylation of proteins during lysis,
tannic acid, which inhibits both PARG and ARH3 (Supplemen-
tary Fig. 2c) as well as PJ34 (a PARP inhibitor) were added
to the lysis buffer. Tryptic digest and subsequent Af1521
enrichment35,36 resulted in a pool of PARylated and MARylated
peptides, which was subjected to demodiﬁcation by either
recombinant ARH3 or PARG (Supplementary Fig. 2d). Sub-
sequent shotgun liquid chromatography (LC)-MS/MS analysis of
three biological replicates revealed that PARG treatment resulted
in the identiﬁcation of many spectra with MARylated peptides,
while ARH3 treatment signiﬁcantly reduced the quantity of
spectra with MARylated peptides (Fig. 2a). Vice versa, the fre-
quency of completely demodiﬁed peptides, i.e., the non-modiﬁed
version of identiﬁed ADP-ribosylated peptides, increased upon
ARH3 treatment (Fig. 2a). Most of the ADP-ribosylated peptides/
proteins detected after PARG treatment were no longer observed
upon ARH3 treatment (Fig. 2b), suggesting that indeed ARH3 is
capable of fully removing PARylation and MARylation from
a
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peptides. We performed LFQ of the ADP-ribosylated peptides
and their non-modiﬁed counterparts based on the MS1 precursor
peak area. This quantitative analysis conﬁrmed that the MARy-
lated peptides detected after PARG treatment were lost when the
peptides were treated with ARH3 instead, which resulted in a gain
of the corresponding unmodiﬁed peptides (Supplementary
Fig. 2e). This data was acquired using HCD peptide fragmenta-
tion, which allows the identiﬁcation of ADP-ribosylated peptides
and the determination of the ADP-ribosylation sites, although we
have recently reported that the accuracy of ADPr acceptor
assignment is difﬁcult when potential acceptor amino acids are
located beside each other due to extensive fragmentation of the
ADP-ribose moiety10,35. In contrast, ETD-based fragmentation
and especially EThcD fragmentation is advantageous for this
task and provides much higher accuracy and conﬁdence for the
localization of the ADPr acceptor site on the identiﬁed peptide.
Therefore, to accurately annotate the modiﬁcation sites for a
part of the modiﬁed peptides, we combined the identiﬁed ADP-
ribosylated peptides from this HCD-based MS measurement
with the exact ADP-ribosylation site localization from a high-
quality dataset that has recently been generated on the same
biological setting using a combined HCD and EThcD
approach10 (Supplementary Data 1). To this end, we adopted
the high-resolution site localization information by matching
the here identiﬁed ADP-ribosylated peptides to the ones we
previously reported in Bilan et al.10. To address which ADP-
ribose acceptor site(s) are speciﬁcally demodiﬁed by ARH3, we
compared the ARH3-treated samples vs the PARG treated
samples and displayed the abundance of ADP-ribosylated pep-
tides and their unmodiﬁed counterparts by a volcano plot
(Fig. 2c). ARH3 demodiﬁed the majority of the Af1521 enriched
PARylated/MARylated peptides, while only a small set of
MARylated peptides could not be demodiﬁed by ARH3. Almost
all monitored peptides with annotated serine-ADPr were sig-
niﬁcantly demodiﬁed by ARH3, while some of the non-
demodiﬁed MARylated peptides contained arginine as ADPr
acceptor site (Fig. 2c), providing strong evidence that ARH3
preferentially demodiﬁes peptides with ADP-ribosylated serine
residues. Since the mapped ADP-ribosylated peptides with
ADPr acceptor sites that had been accurately assigned using the
EThcD were still low in numbers, we also matched our data to
high-scoring HCD fragmentation spectra and repeated the
volcano plot analysis (Supplementary Fig. 2f). Although the site
localization is more promiscuous with the HCD data, this
analysis again strengthened our conclusion that ARH3 com-
pletely demodiﬁes MAR/PARylated serine but not MARylated
arginine.
One of the most prevalent protein groups found among these
spectra to be demodiﬁed by ARH3 consisted of nuclear proteins
including histones. To verify that ARH3 speciﬁcally demodiﬁes
serine ADPr acceptor sites in vivo, we carefully monitored,
among the above described enriched peptide pools, two peptides
with serine ADPr acceptor sites (i.e., H3 and HMGA1) that were
recently published to be modiﬁed at these serine residues37 and
two peptides with known arginine-acceptor sites35 (i.e., P4HB
and PDIA3). Detailed analysis conﬁrmed that the serine sites of
H3 and HMGA1 were signiﬁcantly demodiﬁed by ARH3,
whereas the modiﬁed arginine ADPr acceptor sites of P4HB and
PDIA3 remained equally abundant whether the peptides were
treated with PARG or with ARH3 (Fig. 2d). Thus our data
strongly indicates that ARH3 is a serine mono-ARH in vitro. It
remains to be determined which residue(s) regulate the
speciﬁcity of DraG and ARH1 (both arginine speciﬁc) and
ARH3 (serine preference). Although ARH1 and ARH3 share
amino acid sequence similarity and enzymatically crucial
residues (D77 and D78), the modeling of the electrostatic
surface potentials shows substantial differences between the two
enzymes (Supplementary Fig. 2g). The structural overlap of
DraG with ARH3 revealed that G115 could be a possible
candidate residue confering arginine speciﬁcity (Fig. 1c). How-
ever, mutating residue G115 of ARH3 to aspartate did not
confer arginine-MAR-hydrolase activity when tested on CDTa-
mediated ADP-ribosylated actin (Supplementary Fig. 2g).
ARH3 reduces serine ADP-ribosylation in vivo. With the above
experiments, we showed that human ARH3 is a serine mono-
ARH in vitro. Notably, human and mouse ARH3 share a high
amino acid sequence identity. To address whether ARH3 con-
tributes to the demodiﬁcation of MARylated proteins in vivo, we
thus mapped all ADP-ribosylated peptides (i.e., the ADP-ribo-
sylomes) of WT and ARH3 KO MEFs from mice which both
expressed PARG comparably (Supplementary Fig. 3a). Analyses
of ADP-ribosylated peptides were performed according to a LC-
MS/MS measurement tailored for the analysis of ADP-ribosylated
peptides10,35. Importantly, samples were all treated with PARG
before enrichment and during the MS measurement ADP-ribose
fragment ions were used for the selection of modiﬁed peptides to
produce high-quality HCD as well as EThcD spectra for the
accurate localization of the ADP-ribose modiﬁcation on the
peptide sequence. Notably, the total quantity of ADP-ribosylated
peptides derived from ARH3 KO MEFs tremendously increased
compared to WT MEFs already under basal (i.e., untreated)
conditions (Supplementary Fig. 3b). We found a roughly ﬁve-fold
increase in the number of different ADP-ribosylated peptides,
indicating that ARH3 strongly contributes to the ADP-
ribosylation state of many proteins (Fig. 3a). Most of the iden-
tiﬁed proteins were modiﬁed at only one site, while few were
modiﬁed at several sites (Supplementary Fig. 3c). ARH3 KO
MEFs were earlier described to form PAR with different kinetics
compared to their WT counterparts15. When analyzing the cel-
lular ADP-ribosylome of ARH3 WT vs KO cells treated with 500
μM H2O2 for 60 min, we found an increased number of ADP-
ribosylated peptides in both cell types as expected and described
before for HeLa cells34 but to a much larger extent in ARH3 KO
cells (Fig. 3a and Supplementary Fig. 3b). Interestingly, the
overlapping fraction of modiﬁed peptides comparing WT vs KO
remained signiﬁcant after H2O2 treatment, and many more ADP-
ribosylation sites could be observed in the ARH3 KO cells
(Fig. 3a). Furthermore, there was a substantial overlap of ADP-
ribosylated peptides derived from H2O2-treated WT MEFs and
untreated ARH3 KO cells (Supplementary Fig. 3d). Measurement
of biological replicates conﬁrmed the reproducibility of the bio-
logical ﬁnding and analysis pipeline (Supplementary Fig. 3e).
Utilizing the EThcD-generated ADP-ribosylated peptide spec-
tra, we found that there is a signiﬁcant and speciﬁc increase in the
number of unique serine-ADP-ribosylated sites both in untreated
and in H2O2-treated conditions comparing ARH3 KO to
WT cells (Fig. 3b). Using EThcD spectra with a localization
score of >95%, only peptides with modiﬁed serines could be
identiﬁed. The inclusion of also HCD spectra, which are not ideal
for ADPr site localization, led to the identiﬁcation of more but
also different sites (e.g., lysine residues) (Supplementary Fig. 3f).
Gene ontology analysis revealed that most of the proteins whose
ADP-ribosylation increased in ARH3 KO cells regulate DNA-
associated processes in the chromatin context, although to a
differential extent dependent on the treatment and the cell type
analyzed (Fig. 3c). This is in agreement with the observation that
a large part of ARH3 is associated with chromatin (Supplemen-
tary Fig. 3g). To conﬁrm that the identiﬁed proteins are direct
ARH3 targets, we biochemically validated the demodiﬁcation of
one candidate target, HMGB1. After in vitro ARTD1-dependent
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ADP-ribosylation, ARH3, but not PARG, almost completely
demodiﬁed HMGB1 (Fig. 3d).
Since it was reported that the amino acids surrounding an
ADP-ribosylation site inﬂuence the binding of certain macro-
domains32, we analyzed the amino acid sequence of ARH3-
targeted ADP-ribosylation sites. For this, we created sequence
logos within a 13 amino acid window with the identiﬁed ADP-
ribosylation site in the center. As previously observed by us and
others10,35, we could conﬁrm a primitive KS and a lower
abundant RS motif for a signiﬁcant portion of serine-ADPr sites
in untreated ARH3 KO cells and upon H2O2 treatment of ARH3
WT and KO cells (Fig. 3e), indicating that ARH3 is targeting the
same ADP-ribosylation sites under basal and after H2O2
treatment. A list of all identiﬁed ADP-ribosylated proteins and
peptides can be found in supplementary materials (Supplemen-
tary Data 2).
Finally, based on the observed sequencing motives (Fig. 3e) and
modeling of ADPr in the putative ARH3-binding site, we added
both a KSG and a RSG tripeptide to the ARH3-ADPr model,
restraining each during energy minimization by a covalent bond
between the serine side chain and the ADPr close to E41 (Fig. 3f
and Supplementary Fig. 3h). Interestingly the side-chain termini
of both lysine and arginine next to the modiﬁed serine residue
were capable of adopting a conformation allowing association
with a patch close to the postulated active site having a negative
electrostatic potential, indicating that the neighboring amino
acids of an ADPr acceptor sites might contribute to the binding
and subsequent demodiﬁcation by ARH3. Moreover, in this
model, the modiﬁed serine side chain occupies a cavity lined by
G115. Mutation of this residue to a larger residue such as
aspartate indeed prevented binding (Supplementary Fig. 2a).
In summary, our results provide strong evidence that ARH3 is
responsible for the demodiﬁcation of MARylated as well as
PARylated peptides modiﬁed at a serine residue in vivo with
potentially important consequences on DNA-associated processes
both in physiological and pathological conditions. This data puts
ARH3 in line with PARG as the direct antagonist of nuclear
ARTD-mediated ADP-ribosylation, with ARH3 having the
potential to completely reverse serine protein ADP-ribosylation.
Discussion
We report here that ARH3, in addition to its PAR-degrading
activity, exhibits a serine mono-ARH activity. This is reﬂected by
the fact that ARH3 demodiﬁes MARylated ARTD8. Furthermore,
we showed that ARH3 binds to MARylated peptides and we
identiﬁed crucial amino acid residues responsible for binding and
demodiﬁcation of MARylated targets (Fig. 1). Using MS
approaches, we showed that ARH3 demodiﬁes serine acceptor
sites (Fig. 2). Finally, we provided in vivo evidence for an
important regulatory role of ARH3 in chromatin organization
and gene expression both under physiological and pathological
conditions (Fig. 3).
ARH3 was earlier described to bind free ADP-ribose with
micromolar afﬁnity and to efﬁciently demodify PAR but not
mono-ADP-ribose-arginine, -cysteine, -diphthamide, or -aspar-
agine bonds12,13. The observed demodiﬁcation of H3 in Fig. 1a is
most likely a combination of ﬁrst demodiﬁcation of PARylation
and subsequently de-MARylation of H3 (since PARG reduces the
modiﬁcation to a lesser extent). This is in agreement with the
observation that the mono-ART ARTD8 can be demodiﬁed by
ARH3 but not PARG (Fig. 1b). The ﬁnding of increased fre-
quency of fully demodiﬁed peptides using the in vitro approach
with Af1521-enriched PARylated and MARylated peptides
(Fig. 2) demonstrates, on the molecular level, that the chemical
speciﬁcity of the mono-ARH activity of ARH3 is indeed that of a
glycohydrolase (and not, for instance, of a phosphodiesterase),
since we found no left-over traces of the ADPr modiﬁcation
by MS. Moreover, our unbiased quantitative MS approach
revealed that ARH3 is able to completely demodify ADP-
ribosylated serine but not arginine residues (Fig. 2c, d).
During the revision of the manuscript, Fontana et al. also
reported on the mono-ARH speciﬁcity of ARH3 using an in vitro
system of puriﬁed target proteins as well as WT and mutant
ARTD1 constructs and showed that ARH3 reverses only serine
mono-ADP-ribosylation30. It remains to be shown how the spe-
ciﬁcities of DraG, ARH1, and ARH3 are controlled. Initial
attempts failed to render ARH3 an arginine-speciﬁc ARH by
mutating G115 to aspartate and rather prevented binding to the
MARylated peptide, suggesting that other amino acids contribute
to the speciﬁcity.
Interestingly, different viral macrodomains (e.g., Chikungunya
virus, O’nyong’nyong virus, Sindbis virus, or Venezuelan Equine
Encephalitis virus) have recently been reported to demodify
ARTD8 in vitro38, suggesting that potentially viral macrodomains
might share the target speciﬁcity with ARH3. Whether ARTD8 is
also modiﬁed in vitro at serine residues or at other acceptor sites
(e.g., lyines or glutamic acid) and whether ARH3 is able to
demodify other ADP-ribosylated residues at the proteome-wide
level has to be analyzed further.
ARH3 did not completely demodify several MARylated target
proteins (e.g., ARTD8 or HMGB1; Fig. 1b, remaining modiﬁca-
tion of 30%), indicating that either the tested in vitro conditions
were sub-optimal, that the amino acid sequence might contribute
to the ability of the modiﬁed serine to be demodiﬁed, or that
additional amino acids (e.g., arginines) are MARylated in vitro,
which cannot be demodiﬁed by ARH3. Comparably, PARG and
ARH3 were both unable to reduce the automodiﬁcation of
ARTD1 to undetectable levels (Fig. 1a), raising the question as to
what renders ARTD1 resistant to full demodiﬁcation. This ﬁnd-
ing is, however, in agreement with our earlier observation that
ARTD1 is found to be modiﬁed already under basal conditions in
different cell types34. The inability to demodify ARTD1 could be
due to steric hindrance since the detected acceptor sites span a
rather short domain of ARTD1 and might inhibit full demodiﬁ-
cation or the acceptor-site linkage might not be cleaved (e.g.,
lysine modiﬁcation) due to promiscuous enzymatic activity
in vitro.
The molecular architecture of ARH3 constitutes the archetype
of an all-α-helical protein fold and provides insights into the
reversibility of protein ADP-ribosylation13. Two Mg2+ ﬂanked by
highly conserved amino acid residues pinpoint the active-site
crevice. The structural overlay of DraG and ARH3 provided
insights into a conserved catalytic cleft containing two potentially
catalytically important water molecules. The known D77/78A
mutants have been described before to be important for the
binding of the water molecule. Interestingly, neither the water nor
the Mg2+ ion seem to be important for the binding of the ADP-
ribose to ARH3. Notably, the mutation analysis also provided
evidence that the PAR- and MAR-hydrolase activity are depen-
dent on a large set of common residues. Interestingly, only the
mutation of E41 to Q but not A affected the demodiﬁcation of
MARylated ARTD8. Based on preliminary modeling of a lysine-
and an arginine-containing ADP-ribosylated serine tripeptide, it
is suggested that E41 interacts not only with the magnesium
cations (via binding site water molecules) but possibly in addition
also with the tripeptide backbone. Mutation of E41 to alanine is
anticipated to disturb the water structure surrounding the mag-
nesium cations, with resulting loss of catalytic activity. By con-
trast, mutation of E41 to glutamine may be hypothesized to
interfere with the binding of the ADP-ribosylated serine back-
bone and its ﬂanking amino acid residues.
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ARH3 was localized to mitochondria but is also present in the
nucleus and the cytosol12,39. Our own data provide evidence that
a substantial amount of ARH3 is associated with chromatin
(Supplementary Fig. 3g). Interestingly, most of the identiﬁed
potential ARH3 targets under basal conditions were nuclear
protein previously assigned to DNA-associated processes
(Fig. 3c), indicating that ARH3 is predominantly functionally
relevant in the nucleus under the tested conditions. The detection
of ADP-ribosylated peptides in ARH3 KO MEFs already under
basal conditions strongly suggest that ARH3 contributes to the
demodiﬁcation of proteins under basal conditions, although we
can not exclude that other enzymes might contribute to the
observed increase of the ADP-ribosylome as well (Fig. 3a). It is
currently not known which cellular ARTD is responsible for
ADP-ribosylation under basal conditions. Since many of the
identiﬁed nuclear proteins were modiﬁed at serines upon treat-
ment with H2O2, and H2O2 is known to mainly induce ARTD140,
it is tempting to speculate that the proteins identiﬁed in ARH3
KO cells under unstressed conditions are modiﬁed by ARTD1 as
well. In the presence of ARH3, these proteins might be imme-
diately demodiﬁed and thus not detectable. Whether the same
known molecular mechanisms (e.g., spontaneous DNA lesions,
DNA replication stress) induce ARTD1/2 activation under
unstressed conditions needs to be further clariﬁed. Moreover, due
to the lack of MS-based methods that discriminate between
MARylated and PARylated proteins, we can currently not exclude
that the identiﬁed ADP-ribosylated peptides in ARH3 KO cells
are not only MARylated but, to a certain extent, also PARylated.
However, given that we are not able to detect any signal by
immunoﬂuorescence using an antibody against PAR strongly
indicates that the majority of these peptides are indeed likely
MARylated (Supplementary Fig. 4a). This conclusion is further
supported by the observation that the knockdown of PARG leads
to PAR formation under basal conditions that can be observed by
immunoﬂuorescence using an anti-PAR antibody41,42. The
in vivo experiment also revealed that at least two types of acceptor
sites (i.e., serine and arginine) are mainly modiﬁed in vivo after
H2O2 treatment and that, consistent with the in vitro experiments
(Fig. 2a, b), ARH3 was demodifying the ADP-ribosylated serine
but not the modiﬁed arginine residues. Interestingly, proteins
ADPr-modiﬁed at arginines were described to localize to the
ER34, while the proteins modiﬁed at serines rather localize to the
nucleus. It is tempting to speculate that different ARTs are
responsible for the identiﬁed ADPr acceptor sites.
Besides PARG, ARH3 also participates in nuclear and cyto-
plasmic PAR degradation under oxidative stress conditions, thus
providing a reason why ARH3 KO MEFs were more susceptible
to H2O2-induced cytotoxicity compared to WT MEFs15. In view
of our ﬁndings, ARH3 might, under oxidative stress conditions,
not only protect cells by degrading PAR but also by demodifying
MARylated proteins. It remains to be investigated under which
cellular conditions ARH3 would preferably demodify MARylated
vs PARylated target proteins. This certainly also depends on the
binding afﬁnity of ARH3 to PARylated and MARylated targets.
Along this line, the identiﬁed lysine or arginine residue located
next to the modiﬁed serine residue (Fig. 3e, f) might signiﬁcantly
contribute to the binding of modiﬁed peptides to ARH3 and thus
favor this type of activity.
The functional relevance of the newly identiﬁed protein ADP-
ribosylation sites and the potential crosstalk with other mod-
iﬁcations (e.g., serine phosphorylation) need to be further
investigated. Considering the structural and potentially functional
differences between PARG and ARH3, ARH3 might be an
interesting therapeutical target. Speciﬁc inhibitors of ARH3
activity might help resolving its biological function in cells both
under physiological and pathophysiological conditions.
In summary, we show that the PAR hydrolase ARH3 also has
serine mono-ARH activity and that ARH3 activity very likely
contributes to chromatin organization and DNA-associated
processes, both in physiological and pathological conditions.
Methods
Cloning and protein puriﬁcation. Human ARTD1 was cloned, expressed, and
puriﬁed as previously described43. GST-histone tail fusion proteins (GST-H3 and
GST-H2B tail) were cloned and puriﬁed as previously described44. WT human
ARH1 and ARH3 were cloned using primers (Microsynth) to amplify the sequence
from a purchased cDNA clone (BioCat) by PCR and cloned into pGEX6P-3 using
restriction enzymes BamHI and XhoI (NEB). ARH3 mutants were cloned by site-
directed mutagenesis with fragment and overlap PCRs. The catalytic domain of
mouse ARTD8 (residues 1216–1817) was cloned into pGEX6P-3 using restriction
enzymes BamHI and SalI (NEB). Sequencing of plasmids was performed at
Microsynth.
Plasmids were transformed into BL21 Escherichia coli, and protein expression
was induced by adding 1 mM IPTG at OD600 0.4–0.6 for 3 h at 30 °C. Batch
puriﬁcation of GST-tagged proteins was performed using glutathione sepharose 4B
beads (GE Healthcare) according to the manufacturer’s manual. Expression and
puriﬁcation of all recombinant proteins was analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS–PAGE) followed by Coomassie staining.
In vitro ADP-ribosylation assay with recombinant proteins. To obtain ADP-
ribosylated ARTD1, H3 and H2B tails, and HMGB1, recombinant proteins were
incubated in reaction buffer RB (50 mM Tris-HCl pH 7.4, 4 mM MgCl2 and 250
μM dithiothreitol (DTT)) at a ratio 1:3 (ARTD1 to histone tail) with 100 nM [32P]
NAD+ (Perkin Elmer) and 200 nM of double-stranded annealed 40 bp long oli-
gomer (5ʹ-TGCGACAACGATGAGATTGCCACTACTTGAACCAGTGCGG-3ʹ)
for 15 min at 37 °C. ADP-ribosylation was stopped by adding 10 μM PJ34.
Automodiﬁcation of ARTD8 was carried out in RB with 150 nM [32P]NAD+
and 10 μM cold NAD+ for 1 h at 37 °C. The reaction was stopped by ﬁltering
through an Illustra MicroSpin G-50 column (GE Healthcare) according to the
manufacturer’s manual.
ADP-ribosylation of actin was performed as described earlier45. Brieﬂy, 2 μg β/γ
actin (Cytoskeleton Inc.) was incubated with 50 ng CDTa in the presence of
100 nM [32P]NAD+, 150 μM cold NAD+ and reaction buffer (5 mM HEPES, pH
7.5, 0.1 mM CaCl2, 0.5 mM NaAc, 0.1 mM ATP) at 37 °C. The reaction was
stopped by ﬁltering through a G50 column.
In vitro de-ADP-ribosylation assay. Demodiﬁcation reactions were performed in
RB. Unless otherwise stated, 10 pmol automodiﬁed ARTD1 and 30 pmol trans-
modiﬁed histone tail were incubated with 10 pmol PARG or ARH3 for 15 min at
37 °C. For demodiﬁcation of ARTD8, 30 pmol automodiﬁed recombinant protein
were incubated with 30 pmol PARG or ARH3 for 1 h at 37 °C. Chemical demo-
diﬁcation of ADP-ribosylated actin was performed by addition of 0.5 M hydro-
xylamine and incubation for 15 min at 37 °C or overnight incubation at 37 °C with
the respective hydrolases. Reactions were stopped by adding SDS-loading buffer,
with subsequent boiling at 95 °C for 5 min. Samples were run on an SDS-PAGE gel,
stained with Coomassie Blue, photographed, destained, and exposed on phos-
phorscreens overnight or up to 1 day. Images were taken with a Typhoon FLA 9400
phosphorimager (GE Healthcare). Signal intensities were analyzed and quantiﬁed
using ImageJ. For quantiﬁcation of the MAR hydrolase activity, the signal intensity
(radioactivity and Coomassie) for every stained band was determined using ImageJ.
The radioactivity signal R normalized to the respective Coomassie signal C results
in the speciﬁc modiﬁcation signal S.
S ¼ R
C
The speciﬁc activity A of the demodifying enzyme is given by
A ¼ 1 SX
Si
where SX is the speciﬁc modiﬁcation signal of a given condition (enzyme X) and Si
is the speciﬁc modiﬁcation signal of the input sample.
Pulldown using biotinylated ADP-ribosylated H2B peptide. To test the binding
of ARH3 and PARG, biotinylated ADP-ribosylated or non-modiﬁed H2B peptides
were used. Residue 2 of the peptide (originally an E), was changed to Q in order to
chemically attach ADPr, since solid-phase synthesis of an ADP-ribosylated N-
terminal tetrapeptide of H2B could not be achieved owing to side reactions initi-
ated by migration of the 1-O-glutamyl moiety when an E was present. In contrast,
Q is resistant to acyl migration and thus the so built amide linkage is not cleavable
by ADPr hydrolases32. Peptides were bound to streptavidin sepharose high-
performance beads (GE Healthcare). For each pull-down, 5 µl of beads were
primed by washing three times in binding buffer (50 mM NaCl, 50 mM Tris-HCl
pH 8, 0.05% NP-40) and incubated overnight at 4 °C in 1 ml binding buffer with 5
µg of the modiﬁed or unmodiﬁed peptide. Beads were washed with 1 ml incubation
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buffer (0.1% NP-40, 1× protease inhibitor cocktail (Roche), 50 mM Tris-HCl pH 8,
1 mM DTT, 50 mM NaCl). Thirty pmol of recombinant protein were incubated
with the beads and 1 ml incubation buffer for 3 h at 4 °C. Subsequently, the beads
were washed three times with incubation buffer and once with 1 ml cold
phosphate-buffered saline (PBS) before addition of SDS-loading buffer, sample
boiling, and western blotting.
Cells. MEFs from Arh3+/+ (WT) and Arh3−/− (KO) mice were cultured as pre-
viously described15. HeLa, HEK, and U2OS cells were originally purchased from
ATCC and cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 5% penicillin/streptomycin and 10% fetal calf serum.
Enrichment of ADP-ribosylated peptides from cell lysate. For the PARG/ARH3
peptide demodiﬁcation assay, HeLa cells were treated with 1 mM H2O2 in PBS
containing 1 mM MgCl2 and further processed as described previously35 with the
following alterations: Tannic acid (75 μM) was added to the lysis buffer and PARG
treatment was omitted after tryptic digestion. For every condition, the macro-
domain enrichment was performed in triplicates on 7 mg peptides. The eluted
MARylated and PARylated peptides were reconstituted in 50 mM Tris–HCl, pH 8,
10 mM MgCl2, 250 mM DTT, and 50 mM NaCl. Forty-ﬁve pmol ARH3 or PARG
were added to the peptide mixture and the demodiﬁcation reactions were per-
formed at 37 °C for 1 h. Subsequently, the mixture was ﬁltered through a
Microcon-30 cut off centrifugal ﬁlter (Merck Millipore), acidiﬁed with TFA and
desalted on reverse phase C18 StageTips.
The MEF WT and ARH3 knockout cells were either left in DMEM for 1 h or
treated with 500 µM H2O2 for 1 h in DMEM. After one wash with PBS, cells were
scraped and lysed by adding 6M guanidine-hydrochloride (Gnd-HCl), 5 mM tris
(2-carboxyethyl)phosphine, 10 mM 2-chloroacetamide, and 100 mM Tris pH 8,
95 °C46,47. The samples were diluted with 25 mM Tris, pH 8, and digested with
trypsin (Promega). The peptide mixture was treated with PARG to obtain only
MARylated peptides, and the peptides were enriched using a macrodomain afﬁnity
pull-down as described previously35.
Liquid chromatography and MS analysis. MS analysis for the recombinant
PARG/ARH3 peptide demodiﬁcation assay was performed on an Orbitrap Q
Exactive mass spectrometer (Thermo Fisher Scientiﬁc) coupled to a nano EasyLC
1000 (Thermo Fisher Scientiﬁc). The peptides were loaded onto a self-made col-
umn (75 μm× 150mm), which was packed with reverse-phase C18 material
(ReproSil-Pur 120 C18-AQ, 1.9 μm, Dr. Maisch GmbH). Solvent compositions in
channels A and B were 0.1% formic acid in H2O and 0.1% formic acid in acet-
onitrile, respectively. The peptides were separated at a ﬂow rate of 300 nL/min by a
130 min elution gradient protocol from 2 to 25% B in 100 min, from 25 to 35% B in
10 min, from 35 to 95% in 10 min, and 95% B for 10 min.
The mass spectrometer was set to acquire full-scan MS spectra (300–1700 m/z)
at a resolution of 70,000 after accumulation to an automated gain control target
value of 3 × 106. Charge state screening was enabled, and unassigned charge states
and single charged precursors were excluded. Ions were isolated using a quadrupole
mass ﬁlter with a 2m/z isolation window. A maximum injection time of 250 ms
was set. HCD fragmentation was performed at a normalized collision energy of
25%. Selected ions were dynamically excluded for 30 s.
The identiﬁcation of ADP-ribosylated peptides from MEF cells was performed
on an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientiﬁc),
coupled to a nano EasyLC 1000 liquid chromatograph (Thermo Fisher Scientiﬁc).
We applied an ADP-ribose product-dependent method called HCD-PP-EThcD as
described in ref. 10. Brieﬂy, the method includes high-energy data-dependent HCD,
followed by high-quality HCD and MS when/MS when two or more ADP-ribose
fragment peaks (136.0623, 250.0940, 348.07091, and 428.0372) were observed in
the HCD scan. A detailed description of the MS parameters can be found in ref. 10.
Solvent compositions in channels A and B were 0.1% formic acid in H2O and 0.1%
formic acid in acetonitrile, respectively.
Peptides were loaded onto an Acclaim PepMap 100 (Thermo Scientiﬁc) trap
column, 75 μm× 2 cm, packed with C18 material, 3 μm, 100 Å, and separated on
an analytical EASY-Spray column (Thermo Scientiﬁc, 75 μm× 500mm) packed
with reverse-phase C18 material (PepMap RSLC, 2 μm, 100 Å). Peptides were
eluted over 110 min at a ﬂow rate of 300 nL/min. An elution gradient protocol from
2 to 25% B, followed by two steps, 35% B for 5 min, and 95% B for 5 min was used.
MS data analysis. MS and MS/MS spectra were converted to Mascot generic
format (MGF) by use of Proteome Discoverer, v2.1 (Thermo Fisher Scientiﬁc,
Bremen, Germany). When multiple fragmentation techniques (HCD and EThcD)
were utilized, separate MGF ﬁles were created from the raw ﬁle for each type of
fragmentation. MGF ﬁles were further processed as described10. The MGFs
resulting from measurement following the peptide demodiﬁcation assay were
searched against the UniProtKB human database (taxonomy 9606, version
20140422), which included 35,787 Swiss-Prot entries; 37,802 TrEMBL entries;
73,589 decoy hits; and 260 common contaminants. The MGFs resulting from the
MEF cell measurements were searched against the UniProtKB mouse database
(taxonomy 10090, version 20160902), which included 24,905 Swiss-Prot; 34,616
TrEMBL entries; 59,783 decoy hits; and 262 common contaminants.
Mascot 2.5.1.3 (Matrix Science) was used for peptide sequence identiﬁcation
with previously described search settings48 and some modiﬁcation for the EThcD
searches10. Enzyme speciﬁcity was set to trypsin, allowing up to four missed
cleavages. The ADP-ribose variable modiﬁcation was set to a mass shift of
541.0611, with scoring of the neutral losses equal to 347.0631 and 249.0862. The
marker ions at m/z 428.0372, 348.0709, 250.0940, and 136.0623 were ignored for
scoring. S, R, K, D, and E residues were set as variable ADP-ribose acceptor sites.
Carbamidomethylation was set as a ﬁxed modiﬁcation on C and oxidation as a
variable modiﬁcation on M. Peptides are considered correctly identiﬁed when a
Mascot score >20 and an expectation value <0.05 are obtained. For the ADP-
ribosylation site analyses, peptides identiﬁed with EThcD fragmentation, having a
mascot localization score >95% were used if not stated otherwise.
To perform a LFQ based on the MS1 precursor peak area of the identiﬁed
peptides in the peptide demodiﬁcation assay, Progenesis QI software (v.
3.0.6039.34628, Nonlinear Dynamics, Purham, NC) was applied. Raw data were
imported into Progenesis and aligned based on the MS1 peak retention time. All
samples were normalized based on the total signal intensity to account for sample
loading variations. The obtained results were exported as MGF and searched with
Mascot as indicated above. The Mascot search results were imported into the
Scaffold software (v.4.7.2) and ﬁltered for protein and peptide false discovery rate
(FDR) values of 0.01. When multiple precursors were observed for the same
peptide, the values were summed up to obtain the total level of the peptide. In
order to ensure the correct assignment of the ADP-ribose localization on the
peptide, we compared the here identiﬁed ADP-ribosylated peptides to our high-
quality EThcD dataset published in ref. 10. The so-called demodiﬁed peptides were
obtained by matching the ADP-ribosylated peptides identiﬁed in this experiment to
their identiﬁed non-modiﬁed counterparts.
For the ADP-ribosylation site motif analysis, we used Weblogo49, including
ADP-ribosylated peptides identiﬁed with a mascot localization score >80% and a
sequence window of 6 amino acids around the modiﬁed site. Volcano plot analysis
of the quantiﬁed ADP-ribosylated peptides and their non-modiﬁed counterparts
was performed using two-sample testing in Perseus, with a permutation-based FDR
of 5% and minimal fold change of 250. Gene ontology analysis was performed using
the PANTHER data base51.
Gene expression. MEF cells were washed with PBS before performing RNA
extraction with the NucleoSpin RNA II Kit (Macherey-Nagel). RNA was quantiﬁed
with a NanoDrop (Thermo Fisher Scientiﬁc) and reverse-transcribed according to
the supplier’s protocol (High Capacity cDNA Reverse Transcription Kit, Applied
Biosystems). Quantitative real-time polymerase chain reactions were performed
with KAPA SYBR fast (Kapa Biosystems) and a Rotor-Gene Q 2plex HRM System
(Qiagen).
Chromatin extraction. Cells were washed with 1 ml ice-cold PBS, collected, cen-
trifuged at 1000×g for 5 min at 4 °C and washed twice more with PBS. The pellet
was resuspended is three volumes chromatin extraction buffer (200 mM NaCl,
10 mM HEPES pH 8, 3 mM MgCl2, 0.5 % Triton X-100, 1x protein inhibitor
cocktail (Roche)) and incubated rolling for 30 min at room temperature. Cen-
trifugation at 10,000×g for 10 min at 4 °C gave rise to the soluble fraction
(supernatant). The pellet was resuspended with an equal amount of chromatin
extraction buffer. The soluble fraction was sonicated once for 30 s, the chromatin
fraction three times for 30 s. Protein concentration was measured using a Bradford
assay (Biorad), and samples were subjected to SDS-PAGE and western blotting.
Western blotting. For western blotting analysis, proteins were separated by SDS-
PAGE, and bands were visualized using the Odyssey infrared imaging system (LI-
COR). Antibodies used for western blotting were anti-tetra-HIS (1:1000, Qiagen,
#34670), anti-GST-Z5 (1:1000, Santa Cruz, #sc-459), anti-Tubulin (1:10,000,
Sigma, #T6199), anti-H3 (1:5000 Abcam, #ab1791), anti-ARH3 (1:1000, custom
made, Genosphere Biotech), IRDye 800CW goat anti-rabbit IgG (1:15,000, LI-
COR, P/N 925-32211), and IRDye 680RD Goat anti-Mouse IgG (1:15,000, LI-COR,
P/N 925-68070). Molecular weights are indicated by the PageRuler Plus Prestained
Protein Ladder (Thermo Scientiﬁc). Uncropped western blottings are displayed in
Supplementary Fig. 4.
Modeling. Sequence alignments of human ARH3 and R. rubrum DraG (Uniprot
identiﬁers Q9NX46 and P14300, respectively) were performed using the Clustal
Omega program on the Uniprot webserver52,53. The WITNOTP program (mole-
cular modeling software developed by A. Widmer at Novartis AG, Basel) was used
to protonate all protein and ligand structures and water molecules. In particular,
the side chain of His182 of ARH3 was positively charged for all minimizations as it
is located next ot the phosphate groups of ADPr-Ser. WITNOTP further served to
align protein structures based on their Cα atoms (using the option STRUCTAL-3),
to modify selected atom coordinates and to modify the ADP ribose ligand by
addition of heavy atoms. All minimizations were performed with CHARMM54
using the CHARMM36 forceﬁeld for the protein atoms, water molecules, and
magnesium atoms and the CHARMM general forceﬁeld for each of the ligands55.
Electrostatic potential surfaces, following application of the pdb2pqr software56,57,
were calculated with the Adaptive Poisson-Boltzmann Solver software package58.
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Figures were created with Pymol (The PyMOL Molecular Graphics System, Ver-
sion 1.8 Schrödinger, LLC).
Immunoﬂuorescence. MEF cells were grown on coverslips and treated with H2O2
in DMEM for the indicated times, and immunoﬂuorescence using a homemade
10H antibody was performed as described59 with the following deviations. The
antibody was diluted 1:250, and DNA was stained in a separate step using Hoechst
33258 (Sigma) before mounting.
Data availability. The mass spectrometric proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE60 partner repository with the
dataset identiﬁer PXD008083 and 10.6019/PXD008083. Additional data are
available from the authors upon request.
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